Cancer Immunotherapy and Next-generation Clinical Immune Assessment
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies.
Ngo T, Kuo C, Tu T Biomicrofluidics. 2023; 17(1):011501.
PMID: 36647540 PMC: 9840534. DOI: 10.1063/5.0108792.
Mao C, Beiss V, Fields J, Steinmetz N, Fiering S Biomaterials. 2021; 275:120914.
PMID: 34126409 PMC: 8542346. DOI: 10.1016/j.biomaterials.2021.120914.
Albakri M, Veliz F, Fiering S, Steinmetz N, Sieg S Immunology. 2019; 159(2):183-192.
PMID: 31630392 PMC: 6954739. DOI: 10.1111/imm.13135.
References
1.
Kwak M, Mu L, Lu Y, Chen J, Wu Y, Brower K
. Erratum: single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction. Front Oncol. 2013; 3:78.
PMC: 3619123.
DOI: 10.3389/fonc.2013.00078.
View
2.
Dobrzanski M
. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol. 2013; 3:63.
PMC: 3607796.
DOI: 10.3389/fonc.2013.00063.
View
3.
Ma C, Fan R, Elitas M
. Single cell functional proteomics for assessing immune response in cancer therapy: technology, methods, and applications. Front Oncol. 2013; 3:133.
PMC: 3665942.
DOI: 10.3389/fonc.2013.00133.
View
4.
Milano F, Mari L, van de Luijtgaarden W, Parikh K, Calpe S, Krishnadath K
. Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response. Front Oncol. 2013; 3:137.
PMC: 3665944.
DOI: 10.3389/fonc.2013.00137.
View
5.
Kwak M, Mu L, Lu Y, Chen J, Brower K, Fan R
. Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction. Front Oncol. 2013; 3:10.
PMC: 3565185.
DOI: 10.3389/fonc.2013.00010.
View